Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Companies

Set Alert for Companies

Soriot's Future And MYSTIC Data To Dominate AstraZeneca's 2Q

Impending critical data for AstraZeneca's PD-1 inhibitor Imfinzi, which is expected to be the backbone of the company's growing cancer immunotherapy portfolio, and speculation around CEO Pascal Soriot's recent trip to Israel, where it is rumored he met with a rival pharma company about its vacant chief exec role, will be hot topics during the company's second-quarter earnings call this week.

Business Strategies Leadership ImmunoOncology
Advertisement

Companies

Latest From Companies

Will Mitsubishi's High Offer Price For CNS Target NeuroDerm Deter Others?

Japan's Mitsubishi Tanabe Pharma is offering to buy Israeli CNS specialist NeuroDerm for $1.1bn and the 79% pre-rumor stock price premium may put off other potential suitors.

M & A Companies

Bayer And Morphosys Brush Off ADC Mesothelioma Failure

A mid-stage trial of a Bayer/Morphosys antibody-drug conjugate for mesothelioma has failed, crossing one indication off the list of its potential uses, but development in other indications continues.

Clinical Trials Companies

Roche's Tecentriq Gets The Double At The EU CHMP

Roche's checkpoint inhibitor Tecentriq clears the EU approval hurdle in locally advanced or metastatic urothelial carcinoma and locally advanced or metastatic non-small cell lung cancer.

Approvals Policy & Regulation

'Potential Blockbuster' Dupixent Set For EU Eczema OK

While Dupixent looks set for use in Europe for treating moderate-to-severe atopic dermatitis, analysts believe the biologic has a great future in other indications and could eventually become a blockbuster.

Approvals Biologics

Indian Tax Turbulence Dents Alembic In Q1 - Portends Industry Trend?

Alembic Pharmaceuticals’ first quarter earnings were weighed down by transitional disturbances pertaining to India’s new goods and services tax (GST) regime, potentially signaling an industry-wide trend, although likely temporary.

Companies Commercial

Spanish Biotech Star Oryzon Slumps After Roche Rejection

Barcelona-based Oryzon Genomics remains upbeat about the prospects for 'a first-in-class, best-in-class LSD1 inhibitor' for cancer even though Roche has walked away from what was a potentially lucrative partnership.

Deals Companies
See All
UsernamePublicRestriction

Register